KYVERNA THERAPEUTICS INC (KYTX)

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...

Oversold Conditions For Kyverna Therapeutics (KYTX)

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...

KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation

/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna...

KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...

KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024

KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kyverna Therapeutics (NASDAQ:KYTX) just reported results for the first quarter ...

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies...

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies...

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies...

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12...

Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?

The market's excited for these stocks, but there's no rush to buy them.

Bargain Hunters Take Note: Insider Cluster-Buying At KYTX

Biomanufacturer Invizyne files for proposed $17M IPO (Pending:IZTC.)

Invizyne Technologies (IZTC), a development-stage biomanufacturer, has filed to raise around $17M through an initial public offering. Read more here.

IPOs Broaden in Busy Week With Goldman Bullish on More Deals

Momentum for US IPOs is picking up, as a growing range of firms are attracting buyers — supporting Goldman Sachs Group Inc.’s call that the best is yet to come for the new issues market.

IPO Roundup: Wetouch Technology, Amphitrite Digital, and more (Pending:SUBL)

The US IPO market is reviving after a two-year pause, fueled by Federal Reserve interest rate tweaks and geopolitical uncertainty. Drug developers' trust is ris

Kyverna Therapeutics stock rallies 59% following $319M IPO (NASDAQ:KYTX)

Kyverna Therapeutics (KYTX) stock rallied 59% Thursday afternoon following a $319M initial public offering that priced above its previously proposed range. Read more here.

Biotech Kyverna Surges 36% in Debut After Boosting IPO Size

Kyverna Therapeutics Inc. rose as much as 59% in early trading after its expanded US initial public offering raised $319 million, as drug developers continue to receive a warm welcome from new investors.

Biotech Kyverna Therapeutics Tops IPO Goal to Raise $319 Million

Kyverna Therapeutics Inc. raised $319 million in a US initial public offering priced above a marketed range, as drug developers continue to receive a warm welcome from new investors.

Biotech IPOs Jump More Than 20% as Momentum Builds for Listings

Drug developers are capitalizing on the industry’s momentum by tapping public investors for the first time, as corporate takeovers and a welcoming market lift optimism about biotechnology.

Kyverna Therapeutics upsizes proposed IPO to $297M (Pending:KYTX)

Kyverna Therapeutics (KYTX) has upsized its proposed initial public offering again, this time to $297M from $200M. Read more here.

Kyverna Therapeutics upsizes proposed IPO to $200M (Pending:KYTX)

Biotech company Kyverna Therapeutics (KYTX) has upsized its proposed IPO to $200M from $100M. Read more here.